San Jose, CA – According to filings with the U.S. Securities and Exchange Commission, Visby Medical is raising $156,406,205.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Adam Delazerda played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Visby Medical
At Visby Medical our rapid PCR tests provide accurate and reliable results for healthcare providers all across the United States. We are a medical diagnostics company with portable PCR testing technology that may be implemented in both clinical and mobile laboratory settings. In recent years, healthcare has dominated the public discourse, and as a medical diagnostics company, Visby Medical strives to make access to infectious disease testing as easy and as accessible as possible. Reduce patient anxiety with a PCR test you can run on-site, right at the point of care now available for three critical sexual health targets, in addition to our COVID-19 product. In a world where speed and accuracy in disease testing has become increasingly important, the efficient protection of public health depends on the delivery of fast and reliable infectious disease testing to affected communities as quickly as possible. The Visby Medical portable, instrument-free PCR test delivers results in minutes, not days, making our PCR test kits a revolution in the molecular diagnostics industry. The following are five key benefits to using Visby PCR in your lab or clinic, right at the point of care.

To learn more about Visby Medical, visit http://www.visbymedical.com/

Contact:
Adam Delazerda, Chief Executive Officer
833-468-4729
https://www.linkedin.com/in/adamdelazerda/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved